Transverse Abdominus Plane Block Study

• Status: Not yet recruiting
• Trial end date: 2024-02-12
• Target enrollment: 0
• Participant gender: All

Summary

Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: BB 1101; Bupivacaine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Dexmedetomidine; Ropivacaine

Criteria

Inclusion Criteria:

• provision to sign and date the consent form.

• stated willingness to comply with all study procedures and be available for the duration of the study.

• Male and female patients aged 18 and older

• Benign or malignant colorectal disease undergoing laparoscopic, robotic, or a "hybrid" (minimally invasive dissection with a 6-8 cm incision to complete the surgery) colorectal resection with or without an ostomy

Exclusion Criteria:

• Pregnant or breastfeeding patients

• Medical conditions that may interfere with the use of the study medications (e.g., drug allergy),

• Patients with opioid dependence defined as chronic opioid use more than 3 times per week preoperatively

• Incarcerated individuals

• Age less than 18 years-old

• Urgent/emergent operations as defined by need for operation within 24 hours

• Other conditions or general disability or infirmity that in the opinion of the investigator precludes further participation in the study.

• Enrollment in another concurrent study with use of investigational drugs